Prevalence of erectile dysfunction as long-COVID symptom in hospitalized Japanese patients

Coronavirus disease-2019 (COVID-19) is associated with a wide range of post-acute sequelae. The prevalence of erectile dysfunction (ED) that developed after COVID-19 and the associated underlying factors were analyzed based on a questionnaire survey, COVID-19 Recovery Study II in Japan. A case-control study was conducted with those with or without ED one and two years hospitalized with COVID-19 between March and September 2021. Six hundred and nine Japanese men, with a median age of 48 years, were analyzed. During the study period, 116 subjects (19.0%) had erectile dysfunction. The patients with ED responded with less subjective awareness of recovery and high breathless and fatigue scores compared to those without ED. The patients with ED also showed higher Hospital Anxiety and Depression Scale-D (depression) and the EuroQol 5-dimensions 5-level scores for pain/discomfort and anxiety/depression scores compared before COVID-19 infection. Sleep disturbance was suggested to be associated with erectile dysfunction using an exploratory clustering analysis in the one-year survey. There were no associations of COVID-19 severity, reinfection, vaccination frequency, antiviral treatment for COVID-19 with the presence of erectile dysfunction. It was considered that mental support for the subject with erectile dysfunction as a long-COVID symptom is warranted.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2025-02-21
DOI
https://doi.org/10.1038/s41598-025-88904-6
Citations
3
Primary Topic
Psychosomatic Disorders and Their Treatments
Type
article
Field-Weighted Citation Impact
4.41

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Prevalence of erectile dysfunction as long-COVID symptom in hospitalized Japanese patients

Yuji Takahashi, Shigeki Fujitani, Kensuke Nakamura, Mitsuru Komeya et al.
3 citations
Scientific Reports
Psychosomatic Disorders and Their Treatments
4.41
article

Prevalence of erectile dysfunction as long-COVID symptom in hospitalized Japanese patients

Yuji Takahashi, Shigeki Fujitani, Kensuke Nakamura, Mitsuru Komeya, Nao Ichihara, Taku Oshima, Arisa Iba, Hideki Yoshida, Katsuji Teruya, Toshiyuki Harada, Junji Hatakeyama, Shinichiro Morioka, Yoko Muto, Nobuyuki Nosaka, Shuhei Maruyama, Futoshi Nagashima, Akira Kawauchi, Satoshi Miike, Hayato Taniguchi, Hiroki Saito, Hiroshi Kamijo, Hideaki Kato, Tatsuya Fuchigami, Takeshi Hattori, Takeshi Nishida, Yuichi Sato, Kohei Ota, Hiroyasu Iso, Miyuki Hori, Tomohiro Asahi
article en
3 citations

Abstract

Coronavirus disease-2019 (COVID-19) is associated with a wide range of post-acute sequelae. The prevalence of erectile dysfunction (ED) that developed after COVID-19 and the associated underlying factors were analyzed based on a questionnaire survey, COVID-19 Recovery Study II in Japan. A case-control study was conducted with those with or without ED one and two years hospitalized with COVID-19 between March and September 2021. Six hundred and nine Japanese men, with a median age of 48 years, were analyzed. During the study period, 116 subjects (19.0%) had erectile dysfunction. The patients with ED responded with less subjective awareness of recovery and high breathless and fatigue scores compared to those without ED. The patients with ED also showed higher Hospital Anxiety and Depression Scale-D (depression) and the EuroQol 5-dimensions 5-level scores for pain/discomfort and anxiety/depression scores compared before COVID-19 infection. Sleep disturbance was suggested to be associated with erectile dysfunction using an exploratory clustering analysis in the one-year survey. There were no associations of COVID-19 severity, reinfection, vaccination frequency, antiviral treatment for COVID-19 with the presence of erectile dysfunction. It was considered that mental support for the subject with erectile dysfunction as a long-COVID symptom is warranted.

Scientific ReportsVol. 15(1)
Hiroshima University (JP), Jikei University School of Medicine (JP), Tokyo Medical and Dental University (JP), Kansai Medical University (JP), Shinshu University (JP), Chiba University (JP), St. Marianna University School of Medicine (JP), University of Toronto (CA), Yokohama City University Medical Center (JP), Osaka Prefectural Medical Center (JP), University of the Ryukyus (JP), National Center for Global Health and Medicine (JP), Maebashi Red Cross Hospital (JP), Yokohama City Seibu Hospital (JP), Yokohama City University Hospital (JP), National Hospital Organization Hokkaido Medical Center (JP), Hokkaido hospital (JP), Naha City Hospital (JP), Japan Community Healthcare Organization (JP), Toyooka Hospital (JP), Hitachi General Hospital (JP), Tokyo Metropolitan Tama Medical Center (JP), Yokohama City University (JP), Osaka University of Pharmaceutical Sciences (JP), The University of Osaka (JP)
Ministry of Health, Labour and Welfare
Gender equality
Openalex Percentile: Top 7%
Psychosomatic Disorders and Their Treatments
4.41
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.